Design drug-ready antibodies for any target on the first try, turning months of lab screening into days, so more diseases get candidate medicines faster and cheaper.
PilotStage 3 of 5
Latent-Y agent live with selected partners since March 2026; designs not yet in clinical trials.
Updated 23 Mar 2026·Checked 11 Oct·0 updates this week
Milestones
Next · Partner antibodies reach clinical trials
Launch with $50M12 Feb 2025Complete.
Latent-X: binder design in a browser22 Jul 2025Complete.
Latent-X2: drug-like antibodies zero-shot16 Dec 2025Complete.
Latent-Y design agent for partners23 Mar 2026Complete.
Latent Labs builds AI models that design new proteins, binders and antibodies from scratch for drug makers. Founded by Simon Kohl, a member of DeepMind's AlphaFold 2 team.
AlphaFold predicts the shape of existing proteins; Latent Labs designs new ones that bind a chosen target.
Latent-Y (March 2026) is an agent that runs an antibody design campaign from a written goal to lab-ready designs.
Launched with $50M (Radical Ventures, Sofinnova); models run in London, wet lab in San Francisco.
